HOME >> BIOLOGY >> NEWS
Malignant breast cancer cells to revert to normal with manipulation

Speaking at Experimental Biology 2004, Dr. Mina Bissell describes research showing how manipulation of the extracellular matrix (a network of fibrous and globular proteins that surrounds breast cells) of non-malignant breast cells can lead to genomic instability via oxidative damage. She describes how manipulation of the microenvironment can allow malignant breast cancer cells to revert to normal cells again. She also describes how the tissue culture of the extracellular matrix affects the cancerous cells' resistance to chemotherapy, independently of the characteristics of the malignancy itself.

Her presentation is part of the scientific program of the American Association of Anatomists, one of the six sponsoring societies of this year's Experimental Biology meeting.

Dr. Bissell, a Distinguished Scientist at the Lawrence Berkeley Laboratory, is best known as the researcher who uncovered the critical role of extracellular matrix (ECM) in normal breast function and how its aberration may contribute to breast cancer development. While the role of ECM during embryonic development had been recognized for decades, its important role in tissue-specific function was not appreciated before the work in a handful of laboratories including Dr. Bissell's laboratory. In fact, ECM was regarded as scaffolding for tissues and not much more.

Dr. Bissell postulated in 1981, and later showed experimentally, that the ECM was part of a "dynamic reciprocity" in the social interaction between cells and the nucleus much like hormones and growth factors, with the ECM at times telling the nucleus of the cells what to do and thus directing gene expression in conjunction with these other factors. She had chosen the breast to study the critical role of the ECM in normal breast tissue, a model she had selected because it continues to change throughout life of women in puberty, pregnancy, lactation, and once breast feeding is done (involution). In some of their earliest
'"/>

Contact: Sarah Goodwin
eb4press@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
18-Apr-2004


Page: 1 2 3

Related biology news :

1. Malignant cancer cells generate mice through cloning
2. Certain genes boost fish oils protection against breast cancer
3. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
4. Progress in breast cancer progression
5. The telomere crisis: A crucial stage in breast cancer
6. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
7. More aggressive breast cancer tumors found in African American women
8. Alterations in vitamin D receptor gene increase prostate, breast cancer risk
9. Study links high carbohydrate diet to increased breast cancer risk
10. UCI study reveals gene linked to breast cancer can suppress tumors
11. Animal research suggests plant estrogens in soy do not increase breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Malignant breast cancer cells revert normal with manipulation

(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE San Diego ... provides the connective tissue that enhances care coordination among social ... client-level information; earned a second $1 million grant from the ... in community and; will be recognized as a "Live Well ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
Cached News: